Newsfeeds - Spark Newswire

2 minute read

Innate Pharma Announces HSR Clearance Regarding Expansion Of Its Collaboration With Sanofi On NK Cell Engagers

Today, 2:51 AM

Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cell engagers, the licensing agreement between Sanofi and Innate is now effective. Innate Pharma SA

IPHA

3 minute read

US Stocks Open Lower; Nasdaq Slides Over 100 Points

By Lisa Levin

Today, 2:51 AM

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday.

ACER

1 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 2:51 AM

Gainers 180 Life Sciences (NASDAQ:ATNF) stock rose 75.8% to $2.18 during Tuesday’s pre-market session. The company’s market cap…

APTX

5 minute read

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 2:51 AM

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

ACLX

2 minute read

After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs

By Vandana Singh

Today, 2:51 AM

Innate Pharma SA (NASDAQ:IPHA) and Sanofi SA (NASDAQ:SNY) have expanded their collaboration, with Sanofi licensing a natural killer (NK) cell engager program…

IPHA

2 minute read

News

Sanofi and Innate Pharma Earlier Announced Expanded Collaboration for Natural Killer Cell Therapeutics in Oncology; Innate Will Receive €25M Upfront; Up to €1.35B in Milestones Plus Royalties on Potential Net Sales

By Charles Gross

Today, 2:51 AM

Sanofi (NASDAQ: SNY) and Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate's ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform.

IPHA